Patient Selection for Living Donor Liver Transplantation in Acute-on-chronic Liver Failure

IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY
Abu Bakar H. Bhatti , Syeda F. Qasim , Zamrood Zamrood , Shahzad Riyaz , Nusrat Y. Khan , Haseeb H. Zia , Muslim Atiq
{"title":"Patient Selection for Living Donor Liver Transplantation in Acute-on-chronic Liver Failure","authors":"Abu Bakar H. Bhatti ,&nbsp;Syeda F. Qasim ,&nbsp;Zamrood Zamrood ,&nbsp;Shahzad Riyaz ,&nbsp;Nusrat Y. Khan ,&nbsp;Haseeb H. Zia ,&nbsp;Muslim Atiq","doi":"10.1016/j.jceh.2024.101403","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objectives</h3><p>Acute-on-chronic liver failure (ACLF) is associated with high short-term mortality without liver transplantation (LT). The selection criteria for LT in these patients are not well defined. The objective of this study was to determine factors associated with post-transplant survival in ACLF.</p></div><div><h3>Methods</h3><p>This was a single-center retrospective study of patients who underwent living donor liver transplantation (LDLT) for ACLF between 2012 and 2022. Out of 1093 transplants, 110 patients had underlying ACLF, based on the European Association for the Study of the Liver-Chronic Liver Failure Consortium (EASL-CLIF) criteria. We looked at factors associated with 1-year posttransplant survival.</p></div><div><h3>Results</h3><p>The median model for end-stage liver disease (MELD) score was 33.5 (31–38), and the 1-year posttransplant survival was 72%. Six risk factors were associated with posttransplant survival, namely, body mass index &gt; 30 kg/m<sup>2</sup> [HR, 4.4; 95% CI, 1.8–10.7], platelet count &lt; 66,000/μl [HR, 2.91; CI,1.2–6.6], poor response to medical treatment [HR, 2.6; CI, 1.1–5.7], drug-resistant bacterial or fungal cultures [HR, 4.2; CI, 1.4–12.4], serum creatinine &gt; 2.5 mg/dl [HR, 3.4; CI, 1.5–7.7], and graft-to-recipient weight ratio &lt; 0.7 [HR, 4.8; CI, 1.4–16.3]. The 1-year post-transplant survival was 84% in patients with 0–2 risk factors (n = 89) and was 6% with 3 risk factors (n = 15) (<em>P</em> &lt; 0.001). For 1-year posttransplant survival, the area under curve (AUC) for the current model was 0.8 (0.69–0.9). The AUC for CLIF-ACLF, Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA), and EASL-CLIF ACLF grades was &lt; 0.5.</p></div><div><h3>Conclusion</h3><p>In LT for ACLF, acceptable survival can be achieved when less than three high-risk factors are present.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0973688324000604","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives

Acute-on-chronic liver failure (ACLF) is associated with high short-term mortality without liver transplantation (LT). The selection criteria for LT in these patients are not well defined. The objective of this study was to determine factors associated with post-transplant survival in ACLF.

Methods

This was a single-center retrospective study of patients who underwent living donor liver transplantation (LDLT) for ACLF between 2012 and 2022. Out of 1093 transplants, 110 patients had underlying ACLF, based on the European Association for the Study of the Liver-Chronic Liver Failure Consortium (EASL-CLIF) criteria. We looked at factors associated with 1-year posttransplant survival.

Results

The median model for end-stage liver disease (MELD) score was 33.5 (31–38), and the 1-year posttransplant survival was 72%. Six risk factors were associated with posttransplant survival, namely, body mass index > 30 kg/m2 [HR, 4.4; 95% CI, 1.8–10.7], platelet count < 66,000/μl [HR, 2.91; CI,1.2–6.6], poor response to medical treatment [HR, 2.6; CI, 1.1–5.7], drug-resistant bacterial or fungal cultures [HR, 4.2; CI, 1.4–12.4], serum creatinine > 2.5 mg/dl [HR, 3.4; CI, 1.5–7.7], and graft-to-recipient weight ratio < 0.7 [HR, 4.8; CI, 1.4–16.3]. The 1-year post-transplant survival was 84% in patients with 0–2 risk factors (n = 89) and was 6% with 3 risk factors (n = 15) (P < 0.001). For 1-year posttransplant survival, the area under curve (AUC) for the current model was 0.8 (0.69–0.9). The AUC for CLIF-ACLF, Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA), and EASL-CLIF ACLF grades was < 0.5.

Conclusion

In LT for ACLF, acceptable survival can be achieved when less than three high-risk factors are present.

急性慢性肝功能衰竭活体肝移植的患者选择
背景和目的急性慢性肝功能衰竭(ACLF)与不进行肝移植(LT)的高短期死亡率有关。这些患者接受肝移植的选择标准尚未明确。本研究旨在确定与 ACLF 移植后存活率相关的因素。方法这是一项单中心回顾性研究,研究对象是 2012 年至 2022 年期间因 ACLF 而接受活体肝移植(LDLT)的患者。根据欧洲肝脏研究协会-慢性肝衰竭联盟(EASL-CLIF)的标准,在1093例移植中,110例患者患有潜在的ACLF。结果终末期肝病模型(MELD)评分的中位数为33.5(31-38),移植后1年存活率为72%。六个危险因素与移植后生存率相关,即体重指数为 30 kg/m2 [HR,4.4;95% CI,1.8-10.7]、血小板计数为 66,000/μl [HR,2.91;CI,1.2-6.6]、对药物治疗反应差 [HR,2.6;CI,1.1-5.7]、耐药细菌或真菌培养[HR,4.2;CI,1.4-12.4]、血清肌酐> 2.5 mg/dl [HR,3.4;CI,1.5-7.7]、移植物与受体体重比< 0.7 [HR,4.8;CI,1.4-16.3]。具有 0-2 个危险因素(89 人)的患者移植后 1 年存活率为 84%,具有 3 个危险因素(15 人)的患者移植后 1 年存活率为 6%(P <0.001)。对于移植后 1 年生存率,当前模型的曲线下面积(AUC)为 0.8(0.69-0.9)。CLIF-ACLF、慢性肝衰竭-序贯器官衰竭评估(CLIF-SOFA)和EASL-CLIF ACLF分级的AUC为0.5.结论在LT ACLF患者中,当高危因素少于三个时,可获得可接受的生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical and Experimental Hepatology
Journal of Clinical and Experimental Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
4.90
自引率
16.70%
发文量
537
审稿时长
64 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信